Sign Up to like & get
recommendations!
0
Published in 2018 at "Drug Safety"
DOI: 10.1007/s40264-018-0653-3
Abstract: IntroductionAn extended-release injectable naltrexone suspension (Vivitrol®) was approved in USA in 2010 for the prevention of relapse to opioid dependence. Concerns, raised at the time of approval, about rebound overdose risk following the last dose,…
read more here.
Keywords:
fatal overdoses;
case narratives;
injectable naltrexone;
case ... See more keywords